{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003344","form_type":"8-K/A","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.026753+00:00","generated_at":"2026-06-07T03:09:16.238601+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quince provides EryDel historical financials; FY2022 loss of €12.5M","bullets":["EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.","As of Dec 2022, EryDel cash €1.3M, negative equity €16.5M; operating cash flow used €11.3M.","Quince had $83.2M cash at Sep 30, 2023, expected to fund EryDex Phase 3 trial into at least 2026.","Acquisition adds EryDel's Red Cell Loader platform and Phase 3 therapy for Ataxia-Telangiectasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003344","json":"https://secwatch.observer/filing/0001193125-24-003344.json","markdown":"https://secwatch.observer/filing/0001193125-24-003344.md","text":"https://secwatch.observer/filing/0001193125-24-003344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312524003344/0001193125-24-003344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312524003344/d109820d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:09:16.238601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}